RAmEx Ars MedicaWorld's most comprehensive source of CD-ROMs, videos, slides and books for medical professionals.
About UsContactShopping CartOrder StatusHelpHome
Title Details
Approved Drug Products With Therapeutic Equivalance Evaluations (FDA Orange Book)
Publisher: U. S. Government Publications
Pharmacy & Pharmaceutical Research

See the companion Red Book, which covers pricing.

The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication.
To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January l979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the Introduction.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Approved Drug Products with Therapeutic Equivalence Evaluations publication and its monthly Cumulative Supplements satisfy this requirement. The Addendum to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The Addendum also provides additional information that may be helpful to those submitting a new drug application to the Agency.

Content and Exclusion
The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. [Note: Newly approved products are added to parts 1, 2, or 3 of the List, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.]

This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or United States Adopted Names (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants’ names as abbreviated in this publication; in addition, a list of uniform terms is provided. An Addendum contains drug patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

VideoDisc Approved Drug Products With Therapeutic Equivalance Evaluations (Orange Book ASCII Date File), 34th Edition, 2014, Domestic
Format ASCII Data File
Publisher Catalog Number 917-044-00000-7-DAT-DOM
Copyright Year 2014
Caveat Call For Pricing. This product is non-returnable. No refunds.
   
VideoDisc Approved Drug Products With Therapeutic Equivalance Evaluations (Orange Book ASCII Date File), 34th Edition, 2014, International
Format ASCII Data File
Publisher Catalog Number 917-044-00000-7-DAT-INT
Copyright Year 2014
Caveat Call For Pricing. This product is non-returnable. No refunds.
   
Book Approved Drug Products With Therapeutic Equivalance Evaluations (Orange Book), 34th Edition, 2014, Domestic
Format Loose Leaf
Publisher Catalog Number 917-044-00000-7-DOM
Copyright Year 2014
Caveat This product is non-returnable. No refunds.
$345.00  
Book Approved Drug Products With Therapeutic Equivalance Evaluations (Orange Book Cumulative Supplement), Monthly, 2014, US Domestic Shipment
Format Loose Leaf
Publisher Catalog Number 917-044-00000-7-SP-DOM
Copyright Year 2014
Caveat Must Be Used In Conjunction With the Annual. This product is non-returnable. No refunds.
$345.00  
Book Approved Drug Products With Therapeutic Equivalance Evaluations (Orange Book), 34th Edition, 2014, International
Format Loose Leaf
Publisher Catalog Number 917-044-00000-7-INT
Copyright Year 2014
Caveat This product is non-returnable. No refunds.
$445.00  
Book Approved Drug Products With Therapeutic Equivalance Evaluations (Orange Book Cumulative Supplement), Monthly, 2014, International Shipment
Format Loose Leaf
Publisher Catalog Number 917-044-00000-7-SP-INT
Copyright Year 2014
Caveat Must Be Used In Conjunction With the Annual, This product is non-returnable. No refunds.
$585.00  

Similar Titles
Back to Top
Featured Products
Acland's Video Atlas of Human Anatomy
Stedman's Plus 2002 Medical/Pharmaceutical Spellchecker Win/Mac CD ROM Nursing 2003 Drug Handbook (Springhouse) The Works of Frank H. Netter MedTerms Illustrated USMLE; Step 1,2,3 Drug Topic Red Book


RAmEx Ars Medica, Inc. | 1714 S. Westgate Av. #2 | Los Angeles, California 90025-3852 | USA
International: 1 310 826 4964 | In the USA: 1 800 633 9281 | Fax: 1 310 826 9674
email ramex.com


Advanced Search
Search By Publisher
Search By Specialty
Search By Media
Shopping Cart
1. A Manual of Labora...
Subtotal: $45.95
Checkout
Subscribe to Vidyya Medical News Service

Home | About | Help | Contact | Policy | Shopping Cart | Order Status
Advanced Search | Publishers | Specialties | Media | Keyword | RMA | Site Map
© 2002 RAmEx Ars Medica, Inc.

Medical software, videos, books, netter slides & Stedman reference and more. We have medical software, medical videos, medical books, netter slides & Stedman reference works. We have medical software.

Medical software, videos, books, netter slides & Stedman reference and more.